BRM signs contract with Michigan State University (MSU) to provide research services toward developing a drug treatment for Diabetic Retinopathy

BRM signs contract with Michigan State University (MSU) to provide research services toward developing a drug treatment for Diabetic Retinopathy. In January 2007, BRM signed a contract with Michigan State University (MSU) to provide research services toward developing a drug treatment for Diabetic Retinopathy. As part of the research collaboration BRM is now positioned to evaluate the MSU therapy as a possible treatment for diabetic renal failure. The University of California at San Francisco received a seven year contract totaling $220 Million. The goal of the funding is to perform clinical trials via the Immune Tolerance Network (ITN) (www.immunetolerance.org). ITN and BRM have entered into a contract with University of California at San Francisco to perform preclinical studies in autoimmunity including; Type 1 diabetes, Multiple Sclerosis and Rheumatoid Arthritis.